Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)

Project ACCESS: Advancing Access to HIV/HCV Testing Through Transformation in Syringe Services Programs: A Cluster Randomized Trial

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this study is to test the effectiveness of the ACCESS strategy: an organizational-level intervention that uses funding and practice facilitation to improve the organizational capacity of syringe services programs (SSPs) to implement routine, opt-out HIV and Hepatitis C (HCV) testing and linkage to care for people who inject drugs (PWID).

Who May Be Eligible (Plain English)

Who May Qualify: - SSPs must: 1. be operating in an Ending the HIV Epidemic (EHE) or Centers for Disease Control and Prevention (CDC) determined vulnerable jurisdictions; 2. serve at least 300 unique participants per year; 3. not currently offer opt-out HIV/HCV testing; 4. be capable and willing to prospectively collect aggregated, site-level data on the number of participants who are: i) offered HIV/HCV screening, ii) completed these tests, and iii) linked to care, as well as provide participant demographics; 5. have key staff that consent to participate in study surveys, qualitative interviews and practice facilitation throughout the study. Who Should NOT Join This Trial: - SSPs must not: 1. currently receive or have received Frontline Communities in the United States (FOCUS) funding; 2. have already implemented opt-out HIV/HCV testing. 3. currently participating in SAIA-SSP-HIV (NCT06025435) Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * SSPs must: 1. be operating in an Ending the HIV Epidemic (EHE) or Centers for Disease Control and Prevention (CDC) determined vulnerable jurisdictions; 2. serve at least 300 unique participants per year; 3. not currently offer opt-out HIV/HCV testing; 4. be capable and willing to prospectively collect aggregated, site-level data on the number of participants who are: i) offered HIV/HCV screening, ii) completed these tests, and iii) linked to care, as well as provide participant demographics; 5. have key staff that consent to participate in study surveys, qualitative interviews and practice facilitation throughout the study. Exclusion Criteria: * SSPs must not: 1. currently receive or have received Frontline Communities in the United States (FOCUS) funding; 2. have already implemented opt-out HIV/HCV testing. 3. currently participating in SAIA-SSP-HIV (NCT06025435)

Treatments Being Tested

BEHAVIORAL

ACCESS Intervention

Participants will receive the ACCESS intervention with funding, consisting of up to 16 hours of practice facilitation per month in person and/or virtually. Practice facilitation is training and support on implementation of routine HIV/HCV screening.

BEHAVIORAL

Control Group

Participants will receive a link to the CDC compendium of evidence-based interventions for HIV prevention.

Locations (1)

University of Miami
Miami, Florida, United States